ORGANIC
LETTERS
XXXX
Vol. XX, No. XX
000–000
Synthesis and Biophysical Properties
of Constrained D‑Altritol Nucleic
Acids (cANA)
Michael T. Migawa,* Thazha P. Prakash, Guillermo Vasquez, Punit P. Seth, and
Eric E. Swayze
Department of Medicinal Chemistry, Isis Pharmaceuticals, Inc., 2855 Gazelle Court,
Carlsbad, California 92010, United States
Received June 19, 2013
ABSTRACT
The first synthesis of constrained altritol nucleic acids (cANA) containing antisense oligonucleotides (ASOs) was carried out to ascertain how
conformationally restricting the D-altritol backbone-containing ASO (Me-ANA) would affect their ability to form duplexes with RNA. It was found
that the thermal stability was reduced (cANA/RNA ꢀ1.1 °C/modification) compared to DNA/RNA, suggesting the constrained system results in a
small destabilizing perturbation in the duplex structure.
Some antisense oligonucleotides (ASOs)1 modified with
monomers having a conformationally constrained pento-
furanosyl sugar show an increase in binding affinity with
their complementary mRNA; this has been well documen-
ted in the case of LNA (1, Figure 1).2ꢀ6 LNA can be
thought of as a conformationally restricted 20-OMe RNA,
where the methyl group is constrained to the 40-position,
thereby locking it into its ‘northern’ conformation. When
incorporating this conformational restricted 20-OMe RNA,
i.e. LNA, into an ASO, a large increase in affinity is
observed when paired with complementary RNA. This
observation also holds for a variety of other conformation-
ally restricted analogs, such as cEt-BNA (2),7 R-LNA,8 and
ENA.9
Herdewijn et al. have been studying anhydrohexitol-
based oligonucleotides, where the pyranosyl ring system is
replaced with a hexitol ring system.10ꢀ16 The parent in this
series is hexitol nucleic acid (3, HNA), which was incorpo-
rated intoanASO and reported to possess a strong binding
affinity when duplexed with RNA, in addition to many
(9) Morita, K.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.;
Ishikawa, T.; Imanishi, T.; Koizumi, M. Bioorg. Med. Chem. Lett. 2002,
12, 73.
(1) Antisense Drug Technology: Principles, Strategies, and Applica-
tions, 2nd ed.; Crooke, S. T., Ed.; CRC Press: Boca Raton, FL, 2007.
(2) Lindholm, M. W.; Elmen, J.; Fisker, N.; Hansen, H. F.; Persson,
R.; Moller, M. R.; Rosenbohm, C.; Orum, H.; Straarup, E. M.; Koch, T.
Mol. Ther. 2011, 376.
(10) D’Alonzo, D.; Van Aerschot, A.; Guaragna, A.; Palumbo, G.;
Schepers, G.; Capone, S.; Rozenski, J.; Herdewijn, P. Chem.;Eur. J.
2009, 15, 10121.
(11) Maier, T.; Przylas, I.; Strater, N.; Herdewijn, P.; Saenger, W.
J. Am. Chem. Soc. 2005, 127, 2937.
(3) Petersen, M.; Bondensgaard, K.; Wengel, J.; Jacobsen, J. P.
J. Am. Chem. Soc. 2002, 124, 5974.
(12) Allart, B.; Van Aerschot, A.; Herdewijn, P. Nucleosides Nucleo-
tides 1998, 17, 1523.
(4) Nielsen, C. B.; Singh, S. K.; Wengel, J.; Jacobsen, J. P. J. Biomol.
Struct. Dyn. 1999, 17, 175.
(13) Allart, B.; Khan, K.; Rosemeyer, H.; Schepers, G.; Hendrix, C.;
Rothenbacher, K.; Seela, F.; Aerschot, A. V.; Herdewijn, P. Chem.;
Eur. J. 1999, 5, 2424.
(14) Van Aerschot, A.;Maurinsh, Y.;Allart, B.;Boudou, V.; Herdewijn,
P. Collect. Symp. Ser. 1999, 2, 100.
(5) Braasch, D. A.; Corey, D. R. Chem. Biol. 2001, 8, 1.
(6) Petersen, M.; Wengel, J. Trends Biotechnol. 2003, 21, 74.
(7) Seth, P. P.; Vasquez, G.; Allerson, C. A.; Berdeja, A.; Gaus, H.;
Kinberger, G. A.; Prakash, T. P.; Migawa, M. T.; Bhat, B.; Swayze, E. E.
J. Org. Chem. 2010, 75, 1569.
(15) Wouters, J.; Herdewijn, P. Bioorg. Med. Chem. Lett. 1999, 9,
1563.
(8) Hakansson, A. E.; Wengel, J. Bioorg. Med. Chem. Lett. 2001, 11,
935.
(16) Froeyen, M.; Wroblowski, B.; Esnouf, R.; De Winter, H.; Allart,
B.; Lescrinier, E.; Herdewijn, P. Helv. Chim. Acta 2000, 83, 2153.
r
10.1021/ol401730d
XXXX American Chemical Society